Vanderbilt researchers discover how anthrax bacterium defends itself against structural damage and resists the toxicity of the antimicrobial drug targocil.

A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus.

Using part of an antibody isolated at Vanderbilt that “broadly neutralizes” the human dengue virus, biologists at the University of California San Diego and colleagues have disarmed the mosquito that transmits the disabling and potentially deadly tropical infection.

The increasingly antibiotic-resistant bacterium Acinetobacter baumannii requires zinc to cause infection, and Vanderbilt researchers have identified the zinc uptake system it uses.

An unprecedented view of bacterial products within infected tissues opens new opportunities to explore infection biology and devise novel therapeutic strategies.

Vanderbilt investigators have characterized how a new first-in-class antibacterial drug works, which will guide the development of additional compounds that overcome antibacterial resistance.

Vanderbilt researchers led by Eric Skaar are probing the mechanisms bacteria use when faced with nutrient starvation — a host defense strategy called “nutritional immunity.”